Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pleural Diseases 2Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Non-Muscle Invasive Bladder Neoplasms 1Mesothelioma, Malignant 1Glioma 1Glioblastoma 1Epitheliod Malignant Pleural Mesothelioma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Basal Cell 1

Interventions

Gemcitabine 19Mitomycin 10Docetaxel 7BCG Vaccine 6erdafitinib 5durvalumab 4dodecyl maltoside 4Cystoscopy 4ALT-803 4Radiotherapy 25-aminolevulinic acid hexyl ester 2viscum album peptide 1tremelimumab 1toripalimab 1pirarubicin 1pemigatinib 1monalizumab 1hydroxycamptothecinum 1enfortumab vedotin 1chondroitin sulfate, sodium hyaluronate drug combination 1bicalutamide 1Watchful Waiting 1Urine Specimen Collection 1Transurethral Resection of Bladder 1Surveys and Questionnaires 1Patient Discharge 1Paclitaxel 1Nonsteroidal Anti-Androgens 1Mitozytrex 1Maintenance 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Muscle Invasive Bladder Neoplasms × 1-phenyl-3,3-dimethyltriazene × 1 year × Clear all
NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

TheralaseĀ® Technologies Inc.

Phase 2 Recruiting
90 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚔